SecBot SecBot
SECBOTREPLAY Home › Report › BMRN

BMRN · BioMarin completed its acquisition of Alesta Therapeutics, adding ALE1,…

BioMarin · PRESS-RELEASE filed Sep 1, 2026 at 09:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Sep 1, 2026 at 09:05 ET

BioMarin completed its acquisition of Alesta Therapeutics, adding ALE1, a Phase 1/2a oral small-molecule candidate for hypophosphatasia (HPP), to its skeletal conditions portfolio. No financial terms were disclosed; the deal is a bolt-on pipeline addition for a $12.6B biotech with nine marketed products.

  • Acquisition of Alesta Therapeutics closed; Alesta becomes a wholly owned subsidiary of BioMarin.
  • Lead asset ALE1 is an oral small-molecule therapy for hypophosphatasia (HPP), a rare genetic bone disease.
  • ALE1 is currently in a Phase 1/2a trial assessing safety, tolerability, and PK/PD in healthy volunteers and adults with HPP.
  • No upfront payment, milestone, or royalty terms were disclosed in the press release.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access